TY  - JOUR
AU  - Benito Villalvilla, Cristina
AU  - Rocha Muñoz, Andrés De La
AU  - López Abente, Jacobo
AU  - Eggel, Alexander
AU  - Bottoli, Iván
AU  - Severin, Thomas
AU  - Woisetschläger, Maximilian
AU  - Palomares Gracia, Óscar
PY  - 2022
DO  - 10.1111/all.15567
SN  - 0105-4538
UR  - https://hdl.handle.net/20.500.14352/72684
T2  - Allergy
AB  - BackgroundLigelizumab is an anti-IgE monoclonal antibody binding IgE with higher affinity than omalizumab that is under clinical investigation for several IgE-mediated diseases. We previously showed that omalizumab removes IgE bound to FcεRI on...
LA  - eng
PB  - Wiley
KW  - Allergy treament
KW  - Basic immunology
KW  - Dendritic cells
KW  - IgE
KW  - T cells
TI  - Ligelizumab impairs IgE ‐binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN ‐α production and FOXP3 + Treg generation
TY  - journal article
ER  -